In breast cancer, the percentage of FTO-positive expression in the HER2 overexpression subtype (97.1%) was significantly higher than that in the triple-negative (76.2%) and luminal subtypes (52.2%) (P < 0.001) [37]. The gene discussed is ERBB2; the disease is breast carcinoma.